Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914639 · ClinicalTrials.gov registry record · Phase 1
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
A Phase 1 study of Age-related Macular Degeneration, sponsored by OcuTerra Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 12
- Study locations
NCT02914639: Completed Phase 1 study of Age-related Macular Degeneration, sponsored by OcuTerra Therapeutics.
NCT02914639 is a Phase 1 study of Age-related Macular Degeneration that has completed, run by OcuTerra Therapeutics. The registered enrollment target is 44 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914639, a Phase 1 study of Age-related Macular Degeneration, has completed, sponsored by OcuTerra Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
Primary Outcome
Number and percentage of subjects with no red blood cell counts in the anterior chamber
Conditions Studied
Interventions
- DRUG SF0166 Topical Ophthalmic Solution
Study Locations (12)
Texas
- West Texas Retina Consultants - Abilene
- Retina Research Center, PLLC - Austin
- Texas Retina Associates - Fort Worth
California
- Retina Consultants of Orange County - Fullerton
- Northern California Retina Vitreous Associates Medical Group, Inc - Mountain View
Florida
- Retina Macula Specialists of Miami, LLC - Miami
- Center for Retina and Macular Disease - Winter Haven
Arizona
- Retinal Research Institute LLC - Phoenix
Indiana
- John Kenyon Eye Institute - New Albany
Massachusetts
- Ophthalmic Consultants of Boston - Boston
South Dakota
- Black Hills Regional Eye Institute - Rapid City
Washington
- Spokane Eye Clinical Research - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 1 |
What the finished NCT02914639 record still lists
NCT02914639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which SF0166 Topical Ophthalmic Solution is the first listed.
NCT02914639 lists 12 locations in 8 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT02914639 about?
NCT02914639 is a clinical study titled "Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)". The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
What is the current status of trial NCT02914639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-10-05. Estimated completion is 2017-06-26.
What conditions does trial NCT02914639 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT02914639?
The interventions under investigation include: SF0166 Topical Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02914639?
This trial is sponsored by OcuTerra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914639 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02914639's enrollment target sits among peer trials
44 52nd of 74 higher than 23 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI